Medical Equipment

Tumor Blood Testing Market Size Forecast: Revenue and CAGR by 2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Tumor Blood Testing Industry In 2025?

The size of the tumor blood testing market has expanded significantly over recent years. This market is projected to expand from $5.27 billion in 2024 to reach $5.98 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 13.5%. Historically, this expansion can be ascribed to increased research in genomics and proteomics, a growing patient need for quick test outcomes, the surge in developing targeted therapies that necessitate companion diagnostics, the expanding practice of decentralized diagnostics, and a heightened patient inclination towards sample collection at home.

The tumor blood testing market is projected to experience substantial growth over the next few years. Its valuation is anticipated to reach $9.83 billion in 2029, growing at a compound annual growth rate (CAGR) of 13.2%. This expansion during the forecast period is attributed to several factors, including an increase in the adoption of point-of-care testing solutions, greater clinical validation of novel blood tests, a rise in government and private funding for cancer research, the enhanced availability of high-sensitivity tumor biomarkers, and a growing patient preference for less invasive procedures. Key trends anticipated during this period include advancements in multi-cancer early detection (MCED) tests, progress in companion diagnostics, innovative applications of synthetic biology in diagnostics, the integration of blockchain for data security in diagnostics, and the incorporation of robotics in laboratory processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

What Are The Top Growth Drivers Impacting The Tumor Blood Testing Market Outlook?

The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market in the foreseeable future. Older populations, alongside exposure to risk elements like unhealthy eating habits, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for early detection solutions. Tumor blood testing offers a non-invasive method to identify cancer prior to symptom onset, achieved by detecting specific biomarkers present in the bloodstream. This facilitates prompt diagnosis, allows for initial treatment, enhances patient results, and permits continuous tracking of disease advancement and treatment efficacy. For example, data from May 2024 from the National Cancer Institute, a US-based government entity, indicated that by January 2022, approximately 18.1 million cancer survivors were present in the United States, with forecasts suggesting this number will climb to 26 million by 2040. Consequently, the growing frequency of cancer is a key factor boosting the expansion of the tumor blood testing market.

What Are The Key Segments In The Tumor Blood Testing Market?

The tumor blood testing market covered in this report is segmented as

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Microarray-Based Testing, Mass Spectrometry, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

How Are Trends Influencing The Tumor Blood Testing Market?

Leading companies operating within the tumor blood testing market are concentrating on developing innovative technologies, such as non-invasive liquid biopsy methods, to facilitate early cancer detection, track treatment efficacy, and evaluate disease progression more effectively. These non-invasive liquid biopsy technologies represent diagnostic tests that identify and analyze cancer-related biomarkers from bodily fluids, offering a safer and more convenient alternative to conventional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, introduced the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test designed for cancer monitoring. This assay examines cell-free DNA (cfDNA) fragments within the bloodstream to determine tumor burden and assess the response to treatment. This fragmentome-based liquid biopsy serves as a non-invasive, cost-effective option compared to traditional approaches, requiring only a minimal amount of plasma and yielding results within two weeks.

Who Are The Core Companies Influencing The Tumor Blood Testing Market Landscape?

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

How Is Tumor Blood Testing Market Demand Varying Across Different Regions?

North America was the largest region in the tumor blood testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor blood testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Tumor Blood Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp

Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2025, By The Business Research Company

Solid Tumor Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Hemato Oncology Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795